TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 10/30
$1.87+0.05 (+2.75%)
Close on Nov 13, 2026Market cap $21.64MP/E 187.0Yield –
TherapeuticsMD price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
TherapeuticsMD's price to sales ratio was 6.5× on Nov 11, 2026, against 7.0× a year earlier. Over the last 5 years it ranged from 0.3× to 63.5×, with a median of 6.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.5× | −0.2 |
| 2025 | Dec 31, 2025 | 6.7× | +0.5 |
| 2024 | Dec 31, 2024 | 6.2× | +5.9 |
| 2023 | Dec 29, 2023 | 0.3× | −2.3 |
| 2022 | Dec 30, 2022 | 2.6× | +1.0 |
| 2021 | Dec 31, 2021 | 1.7× | −4.0 |
| 2020 | Dec 31, 2020 | 5.7× | −9.4 |
| 2019 | Dec 31, 2019 | 15.0× | −44.5 |
| 2018 | Dec 31, 2018 | 59.5× | −16.7 |
| 2017 | Dec 29, 2017 | 76.3× | +20.9 |
| 2016 | Dec 30, 2016 | 55.3× | −42.9 |
| 2015 | Dec 31, 2015 | 98.2× | +33.8 |
| 2014 | Dec 31, 2014 | 64.5× | −133.4 |
| 2013 | Dec 31, 2013 | 197.8× | +131.4 |
| 2012 | Dec 31, 2012 | 66.4× | – |
See a number that looks wrong?